FFO
REGN icon

Fortitude Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

Fortitude Family Office’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$35.6K Buy
47
+19
+68% +$14.4K 0.01% 590
2026
Q2 		$17.5K Buy
28
+3
+12% +$2.04K ﹤0.01% 571
2026
Q1 		$19.3K Buy
25
+14
+127% +$10.7K ﹤0.01% 439
2025
Q4 		$8.49K Sell
11
-4
-27% -$2.72K ﹤0.01% 632
2025
Q3 		$8.43K Sell
15
-3
-17% -$1.7K ﹤0.01% 626
2025
Q2 		$9.45K Sell
18
-36
-67% -$20.1K ﹤0.01% 577
2025
Q1 		$34.2K Hold
54
– – 0.01% 290
2024
Q4 		$38.5K Sell
54
-2
-4% -$1.68K 0.01% 304
2024
Q3 		$58.9K Hold
56
– – 0.02% 218
2024
Q2 		$58.9K Buy
56
+21
+60% +$20.4K 0.03% 156
2024
Q1 		$33.7K Hold
35
– – 0.02% 199
2023
Q4 		$30.7K Buy
+35
New +$28.8K 0.02% 230

Other funds holding REGN

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Fortitude Family Office's REGN Position: Q3 2026 in Review

Fortitude Family Office increased its Regeneron Pharmaceuticals (REGN) stake by 68% in Q3 2026, buying an estimated $14.4K and bringing the position to 47 shares worth $35.6K. The position accounts for 0.01% of the portfolio, ranked #590.

Fortitude Family Office first reported a position in REGN in Q4 2023 and has held it in 12 quarters since. The position peaked at $58.9K in Q3 2024. 178 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Fortitude Family Office held 47 shares of Regeneron Pharmaceuticals worth $35.6K as of Q3 2026.
  • Fortitude Family Office bought 19 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $14.4K.
  • Regeneron Pharmaceuticals made up 0.01% of Fortitude Family Office's portfolio in Q3 2026, its #590 holding.
  • Fortitude Family Office first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • Fortitude Family Office's Regeneron Pharmaceuticals position peaked at $58.9K in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.